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Background and aims: The soluble receptor for advanced glycation end products (sRAGE) has been
implicated in diabetic vascular complications. We have examined the association between sRAGE and
cardiac markers [NT-proBNP and cardiac troponin T (cTnT)] and subclinical vascular markers in older
men with and without diabetes.
Methods: We performed a cross-sectional study of 1159 men aged 71e92 years with no history of car-
diovascular disease (myocardial infarction, stroke, heart failure, coronary artery bypass graft operation or
angioplasty). Prevalent diabetes included men with a doctor diagnosis of diabetes, men with fasting
glucose 7 mmol/l or HbA1c  6.5% (N ¼ 180). Subclinical vascular measurements included carotid
intima media thickness (cIMT), arterial stiffness [pulse wave velocity (PWV)], central aortic blood
pressure and arterial wave reﬂections [central augmentation pressure (AP) and augmentation index
(AIx)].
Results: sRAGE was strongly and positively associated with renal dysfunction in men with and without
diabetes. sRAGE was signiﬁcantly and positively associated with NT-proBNP (but not cTnT) and AP and
AIx in both groups of men after adjustment for CVD risk and metabolic risk markers, renal function and
inﬂammation. However, no association was seen between sRAGE and central aortic blood pressure, cIMT
or arterial stiffness as determined by PWV in either group.
Conclusions: Higher plasma sRAGE was associated with increased NT-proBNP and markers of arterial
wave reﬂections in men both with and without diabetes. Increased sRAGE may contribute to or be a
marker of worsening cardiac dysfunction or HF. Further studies with cardiac imaging data are required to
conﬁrm this.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Advanced glycation end products (AGEs) are bioactive mole-
cules found in high amounts in the western diet, which have been
implicated in the pathogenesis of atherosclerosis and heart failure
(HF), particularly in patients with diabetes [1e4]. Numerous studies
highlight the interaction between AGEs with their receptor (RAGE),and Population Health, UCL
London, NW32PF, UK.
annamethee).
r Ireland Ltd. This is an open acceswhich is expressed in the vasculature, kidney and inﬂammatory
cells, as a potential contributor to increased oxidative stress and
inﬂammation, vascular endothelial dysfunction and arterial stiff-
ening [1,2]. Enhanced accumulation of AGEs is not just restricted to
diabetes but also occurs with natural aging [5]. AGEs may also
contribute to the development of vascular disease in non-diabetic
people through their pro-oxidant properties [5e7].
The soluble receptor for advanced glycation end products
(sRAGE) is the isoform of RAGE found in serum and is formed by
proteolytic cleavage of RAGE [1]. sRAGE appears to act as a decoy for
capturing circulating AGEs, preventing them from binding to thes article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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inﬂammatory effect of RAGE signalling [1]. While infusion of
AGEs is thought to result in upregulation of cell-bound RAGE
expression in cardiac tissue, administration of recombinant sRAGE
has been shown to inhibit the development and progression of
atherosclerosis in animal models [1]. However, the role of sRAGE in
cardiovascular disease is still contentious. Circulating sRAGE is
strongly associatedwith increased circulating levels of AGEs in both
people with diabetes and without diabetes, and is shown to reﬂect
tissue RAGE expression [8]. Data predominantly from participants
in clinical trials have shown sRAGE to be associated with the
development of CVD complications and mortality in patients with
type-1 and type-2 diabetes [9e12]. It is suggested that sRAGE,
which is easily measured in plasma and serum, could be used to
monitor diabetic vascular disease risk as well as to evaluate the
effect of potential intervention with a view to modulating sRAGE
[13]. However, other studies, largely in people without diabetes,
have shown sRAGE to be inversely associated with CVD [14e17],
and less is known about the clinical signiﬁcance of sRAGE in the
general aging population. Non-invasive vascular markers and
central haemodynamic measurements (including aortic PWV,
central aortic blood pressure and arterial wave reﬂection) are
important markers of early arterial or vascular damage and provide
potential proxy indicators of CVD risk [18e22]. To address the
controversy regarding the possible role of sRAGE in CVD, we have
investigated the association between circulating sRAGE and early
markers of vascular disease including arterial stiffness [pulse wave
velocity (PWV)], central aortic blood pressure, arterial wave re-
ﬂections [central augmentation pressure (AP), augmentation index
(AIx)] and intima-media thickness (IMT), as well as biomarkers of
subclinical myocardial injury and stress [cardiac troponin T (cTnT)
and N-terminal pro B-type natriuretic peptide (NT-proBNP)],
separately in those with and without diabetes. We hypothesised
that sRAGE would be associated with myocardial damage/
dysfunction and subclinical vascular disease before the develop-
ment of overt cardiac disease and that these associations may
depend on the individual's diabetic status.
2. Patients and methods
The British Regional Heart Study is a prospective study, which
recruited a socioeconomically and geographically representative
cohort of 7735 men from 24 British towns between 1978 and 1980.
In 2010e2012, all surviving men (n ¼ 3137), aged between 71 and
92 years, were sent a postal questionnaire and invited for a 30th
year re-examination. 2137 (68%) men completed the postal ques-
tionnaire and 1722 (55%) men attended the re-examination [23].
Ethical approval has been obtained from all relevant local research
ethics committees. Blood samples were collected after fasting for a
minimum of 6 h and were stored at 70 C. The men were asked
whether a doctor had ever told them that they had myocardial
infarction (heart attack, coronary thrombosis), stroke, heart failure
or diabetes and to bring their medication to the examination ses-
sion. They were also asked if they had been told by their doctor if
they had narrowing or hardening of the leg arteries (including
claudication) and whether they had ever had a coronary artery
bypass graft operation (CABG) or angioplasty (percutaneous coro-
nary intervention).
2.1. Cardiovascular risk factors
Anthropometric measurements including body weight and
height were carried out. Body mass index (BMI) was calculated as
weight/(height)2 (kg/m2). Details of measurements and classiﬁca-
tion methods for smoking status, alcohol intake and physicalactivity have been described [24]. The use of antihypertensive
medication was based on self-reported medication history and
review of codes from the British National Formulary (BNF). Blood
pressure was measured using an Omron blood pressure recorder
twice in succession in the right arm, with the subject seated and the
arm supported, and the mean of the two blood pressure recordings
was used. Plasma glucose was measured by a glucose oxidase
method using a Falcor 600 automated analyser. HbA1c was
measured in whole blood using high performance liquid chroma-
tography. Serum insulin was measured using an ELISA assay, which
does not cross-react with proinsulin. Glucose and insulin concen-
trations were adjusted for the effects of fasting duration and time of
day [25]. Predicted glomerular ﬁltration rate (eGFR) (measure of
renal function) was estimated from serum creatinine using the
equation eGFR ¼ 186  (Creatinine/88.4)1.154 x (Age)0.203 [26]. C-
reactive protein (CRP) was assayed by ultra-sensitive nephelometry
(Dade Behring, Milton Keynes, UK). Plasma levels of IL-6 were
measured with ELISA (R&D Systems, Oxford, UK). Prevalent dia-
betes included men with a doctor-diagnosed diabetes and men
with fasting blood glucose 7 mmol/l or men with HbA1c  6.5.
2.2. NT-proBNP and cardiac troponin T
NT-proBNP and cTnT were measured in plasma samples on an
automated clinically validated immunoassay analyser (e411, Roche
Diagnostics, Burgess Hill, United Kingdom) using the manufac-
turers' calibrators and quality control reagents [27]. The lower limit
of sensitivity was 5 pg/ml for NT-proBNP and 3 pg/ml for cTnT. Low
control coefﬁcient of variation (CV) was 6.7% and high control CV
was 4.9%.
2.3. Plasma sRAGE
Plasma sRAGE was measured in samples stored at 80 C until
assay, using a commercially available ELISA (R&D Systems, Oxon,
UK). The control intra-assay coefﬁcient of variation (CV) was 2.7%,
and inter-assay CV was 9.3%.
2.4. Non-invasive cardiovascular markers
Measurements were measured by two vascular technicians in
series. Left and right carotid arteries were images using a Z.One
Ultra ultrasound system (Zonare Medical Systems, Mountain View,
CA) with a 5e10-mHz linear probe. A cross sectional sweep from
the base of the common carotid artery to the jaw bone and longi-
tudinal images of the common carotid artery approximately 1 cm
proximal to the carotid bifurcationwere recorded. Peak systolic and
end-diastolic common carotid artery diameter and carotid intima
media thickness (CIMT) (the distance between the leading edge of
the intima and the media-adventitia interface) were measured
using the Carotid Analyser software (Medical Imaging Applications,
Iowa City, IA). From the longitudinal images, a region of interest
(5e10mm)was selected in a plaque free area, at least 1 cm from the
bifurcation. cIMTwasmeasured from three end-diastolic images on
each side and a mean of these measures was calculated. Maximum
and minimum carotid artery diameter was assessed from three
consecutive waveforms and mean distension was calculated. The
distensibility coefﬁcient was then calculated using the following
formula, as described by Dijk et al.: distensibility coefﬁcient
(DC) ¼ [(2 mean distension/baseline diameter)/mean pulse
pressure (kPa)]*1000 [28]. There was good agreement between the
vascular technicians in ultrasound-based measurements. With re-
gard to the inter- and intra-observer reproducibility, the coefﬁcient
of variation (CV) for cIMT (n ¼ 109) was 7.1% and 5.1% respectively.
The corresponding inter and intra-observer reproducibility CV for
Fig. 1. Histogram of the distribution of sRAGE in men with and without diabetes.
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The Vicorder (Skidmore Medical, Bristol UK) was used to assess
brachial artery waveforms and carotid to femoral pulse wave ve-
locity (PWV). Brachial artery waveforms were recorded with the
participant seated with a Hokanson SC10 cuff positioned around
the middle of the right upper arm. A blood pressure measurement
was taken ﬁrst and then the cuff was reinﬂated to diastolic pressure
and, when a good quality stable waveformwas achieved, the signal
was recorded. Central blood pressure (BP), augmentation pressure
(AP) and the augmentation index (AIx) were all derived from the
pulse waveform using a brachial-aortic transfer functionwithin the
Vicorder software. Two readings of AP within 5 mmHg and AIx
within 5% of each other were accepted and averaged. PWV was
assessed with participants in a semi-supine position with their
torso at approximately 30. A 2  9 cm cuff was positioned around
the neck with the bladder over the right carotid pulse, and a
Hokanson SC10 cuff around the middle of the right thigh. Path
length was measured from the sternal notch to the centre of the
thigh cuff. The cuffs were simultaneously inﬂated and traces with a
minimum of 3 good quality waveforms recorded. Two PWV mea-
surements, within 0.5 m/s of each other, were accepted and
averaged.
2.5. Statistical analysis
Distributions of HbA1c, glucose, insulin, CRP, IL-6, NT-proBNP
and cTnT were highly skewed and log transformationwas used. The
men were divided into equal quartiles based on the sRAGE distri-
bution in all men (<6.65, 6.65e6.94, 6.95e7.23 and >7.24 pg/l). For
comparisons of baseline characteristics, logistic regression and
linear regression were used to test for trends, ﬁtting sRAGE in its
original continuous form. Multiple linear regression models were
used to assess the association between sRAGE and cardiac markers
and subclinical vascular disease measures. In multivariate analyses,
use of antihypertensive treatment was ﬁtted as categorical vari-
ables whilst age, body mass index (BMI), eGFR, LDL-C, IL-6, insulin,
heart rate and NT-proBNP were ﬁtted as continuous variables. All
analyses were performed using SAS version 9.3 (SAS, Cary, North
Carolina).
2.6. Study sample
This present study is a cross-sectional analysis of the data from
the 2010e2012 examination. Of the 1722menwho attended the re-
examination, sRAGE measurements were available in 1603 men.
Men with prior clinical diagnosis of CVD were deﬁned as men with
a self-reported doctor diagnosis of CHD, stroke, heart failure or men
who had reported a CABG or angioplasty (n¼ 444). Patient recall of
a doctor diagnosis of CHD has been shown to be a valid measure of
recording diseases in this study population [29] and [30]. The kappa
statistics comparing health record review with patient's recall of
CHD was 0.82 [29]. Men with prevalent CVD showed signiﬁcantly
higher mean sRAGE [mean (SD) 7.03 (0.60)] compared to those
without prevalent CVD [mean (SD) 6.94 (0.49)] (p ¼ 0.002) and
were excluded, leaving 1159 men for analysis.
3. Results
In men with no prior clinical diagnosis of CVD, those with dia-
betes (N ¼ 180) showed similar mean sRAGE (SD) compared to
those with no diabetes (N ¼ 979) [6.96 (0.52) vs. 6.94 (0.49)]. Fig. 1
shows the distribution of sRAGE in those with and without dia-
betes. Table 1 shows the baseline characteristics by quartiles of the
sRAGE distribution, separately in men without CVD, with and
without diabetes. In those without diabetes, sRAGE was positivelyand signiﬁcantly associated with age and eGFR (renal dysfunction)
but was inversely associated with BMI, blood glucose, insulin, heart
rate, and to a lesser extent with IL-6. In men with diabetes, sRAGE
also related positively to age and eGFR but weak positive associa-
tions were seenwith IL-6, and a signiﬁcant positive associationwas
seen with use of antihypertensive treatment. In contrast to those
without diabetes, no associationwas seen between sRAGE and BMI,
glucose, insulin or heart rate.3.1. sRAGE and vascular measurements
sRAGE was positively and signiﬁcantly associated with the car-
diac markers NT-proBNP and cTnT and the haemodynamic pa-
rameters central AP and AIx in both menwith and without diabetes
(Table 2). A weak positive association was seen with aortic central
BP. No association was seen with aortic or carotid stiffness (PWV
and distensibility respectively) or cIMT in either group. Fig. 2 shows
the correlation and linear regression line between sRAGE and NT-
proBNP, cTnT, central AP and AIx. The association between sRAGE
and NT-pro-BNP (but not cTnT), AP and AIx remained after
adjustment for factors shown to be associated with sRAGE in
Table 1, and known to be associated with CVD including age, BMI,
eGFR, antihypertensive treatment, LDL-c, insulin and IL-6. Results
were similar if glucose was used instead of insulin. The adjusted b
regression coefﬁcients for sRAGE are presented in Table 3. Further
adjustment for heart rate made only minor differences to the as-
sociations. The association between sRAGE and AP and AIx was
attenuated, but remained signiﬁcant after further adjustment for
NT-proBNP (Table 3). In a sensitivity analysis, we further excluded
23 men who reported claudication. This made little difference to
the ﬁndings.
Table 1
Baseline demographic, clinical and metabolic characteristics by quartiles of SRAGE in 1159 men with and without diabetes.
Men with no diabetes (N ¼ 979)
sRAGE (quartiles)
p-trend
1 (lowest) (N ¼ 251) 2 (N ¼ 243) 3 (N ¼ 244) 4 (highest) (N ¼ 241)
SRAGE (pg/l) 6.34 (0.26) 6.79 (0.09) 7.08 (0.09) 7.56 (0.27)
Age (years) 77.98 (4.44) 77.87 (4.62) 78.85 (4.84) 79.05 (5.07) 0.0002
BMI (kg/m2) 27.21 (3.62) 26.54 (3.80) 26.44 (3.21) 25.84 (3.47) <0.0001
% smokers 2.4 4.7 4.0 3.2 0.54
% inactive 22.6 20.8 22.1 22.1 0.90
% manual 38.03 46.5 46.3 41.9 0.50
% moderate/heavy drinkers 8.2 5.4 4.2 2.6 0.002
% with PVDa 0.8 2.9 3.0 1.3 0.96
Antihypertensive treatment 45.4 42.4 48.0 41.9 0.60
SBP (mmHg) 147.9 (17.5) 149.8 (18.0) 147.6 (18.3) 148.3 (19.1) 0.67
LDL-C (mmol/l) 2.86 (0.89) 2.89 (0.85) 2.93 (0.94) 2.99 (0.99) 0.05
HDL-C (mmol/l) 1.53 (0.44) 1.56 (0.45) 1.46 (0.37) 1.49 (0.45) 0.14
Glucose (mmol/l)b 5.37 (4.98e5.76) 5.37 (5.04e5.64) 5.26 (4.95e5.58) 5.26 (4.89e5.53) 0.006
Insulin (IU)b 7.46 (5.16e10.92) 7.69 (5.25e11.50) 7.39 (5.11e10.70) 6.04 (4.63e9.52) 0.04
eGFR (ml/min/1.73 m2) 78.76 (15.95) 76.36 (15.81) 73.08 (16.93) 68.79 (17.59) <0.0001
CRP (mg/l)b 1.57 (0.65e3.36) 1.30 (0.52e2.78) 1.30 (0.71e2.62) 1.30 (0.67e2.50) 0.15
IL-6 (ng/ml)b 3.25 (1.97e4.64) 2.80 (1.75e4.23) 2.89 (1.73e4.18) 2.77 (1.74e4.03) 0.10
Heart rate (beats/min) 70.91 (14.35) 67.27 (12.42) 66.47 (12.58) 66.87 (12.02) 0.01
Men with diabetes (N ¼ 180)
1 (N ¼ 46) 2 (N ¼ 42) 3 (N ¼ 45) 4 (N ¼ 47)
sRAGE (pg/l) 6.32 (0.30) 6.83 (0.08) 7.08 (0.08) 7.58 (0.29)
Age (years) 77.38 (3.79) 78.10 (4.74) 78.86 (4.13) 78.92 (4.76) 0.03
BMI (kg/m2) 28.86 (3.43) 28.69 (3.69) 27.97 (4.51) 29.83 (4.87) 0.99
% smokers 4.4 2.1 4.3 4.2 0.35
% inactive 29.6 11.6 26.1 23.3 0.39
% manual 60.9 52.4 48.9 66.0 0.63
% moderate/heavy drinkers 4.4 2.6 6.8 6.5 0.40
% with diagnosed PVDa 2.3 0 2.3 4.6 0.62
Antihypertensive treatment 56.5 57.1 73.3 70.2 0.05
SBP 145.2 (20.8) 144.5 (20.9) 140.9 (18.7) 143.5 (22.3) 0.95
LDL-C (mmol/l) 2.46 (0.86) 1.90 (0.85) 2.03 (0.81) 2.01 (0.59) 0.03
HDL-C (mmol/l) 1.35 (0.39) 1.28 (0.36) 1.40 (0.52) 1.22 (0.37) 0.81
Glucose (mmol/l)b 7.24 (5.99e8.06) 7.02 (6.01e7.85) 7.00 (6.15e8.03) 7.39 (5.82e9.02) 0.51
Insulin (IU)b 10.48 (6.08e18.00) 9.03 (6.06e13.20) 14.43 (9.30e22.84) 14.30 (10.20e21.19) 0.44
eGFR (ml/min/1.73 m2) 78.31 (14.83) 75.56 (17.98) 71.53 (16.93) 57.42 (17.72) <0.0001
CRP (mg/l)b 1.75 (0.85e3.58) 1.01 (0.64e1.80) 1.16 (0.49e2.48) 1.63 (0.65e4.59) 0.55
IL-6 (ng/ml)b 3.00 (1.88e4.77) 3.00 (1.94e5.21) 2.83 (1.65e4.85) 3.97 (2.39e7.19) 0.30
Heart rate (beats/min) 67.76 (11.16) 65.95 (13.65) 67.78 (11.23) 70.15 (14.79) 0.29
Mean and standard deviation unless speciﬁed.
a Peripheral vascular disease deﬁned as self-reported doctor diagnosis of narrowing or hardening of the leg arteries (including claudication).
b Geometric mean (interquartile range).
Table 2
Cardiac markers and subclinical vascular measurements by quartiles of SRAGE in men with and without diabetes.
sRAGE (quartiles) p-trend
1 (lowest) 2 3 4 (highest)
Men with no diabetes
NT-proBNP (pg/ml)a 104.6 (54e240) 93.7 (57e187) 129.0 (67e247) 152.9 (68e345) <0.0001
cTnT (pg/ml)a 10.17 (6.57e15.3) 9.39 (6.83e13.41) 10.28 (7.17e15.32) 11.13 (7.26e16.74) 0.006
Central aortic blood pressure (mmHg) 59.19 (12.59) 60.94 (12.21) 61.37 (13.91) 61.21 (13.56) 0.13
Central augmentation pressure (mmHg) 11.47 (4.72) 12.89 (4.60) 13.32 (3.36) 13.29 (5.32) 0.0005
Augmentation index (%) 18.99 (6.05) 21.04 (5.91) 21.42 (6.13) 21.35 (6.36) 0.0003
PWV (m/s) 10.36 (1.62) 10.04 (1.78) 10.14 (1.62) 10.35 (1.82) 0.21
DC (103 kPa1) 12.02 (3.96) 12.47 (4.52) 11.96 (4.00) 12.37 (4.22) 0.66
cIMT (mm) 0.80 (0.16) 0.80 (0.15) 0.81 (0.16) 0.80 (0.15) 0.58
Men with diabetes
NT-proBNPa 79.0 (50e140) 111 (64e235) 131.6 (71e343) 164.0 (76e282) 0.006
cTnT (pg/ml)a 8.94 (6.38e13.10) 12.30 (8.19e18.52) 11.25 (7.31e18.00) 15.64 (10.36e26.84) 0.0002
Central aortic blood pressure (mmHg) 59.93 (13.27) 62.14 (13.57) 59.80 (13.98) 64.44 (12.72) 0.25
Central augmentation pressure (mmHg) 11.58 (4.71) 13.46 (4.91) 12.16 (4.18) 14.20 (6.36) 0.02
Augmentation index (%) 19.31 (5.52) 21.50 (6.89) 20.16 (4.94) 22.03 (7.51) 0.04
PWV (m/s) 10.40 (1.53) 10.39 (1.57) 10.02 (1.43) 10.25 (1.20) 0.31
DC (103 kPa1) 12.50 (4.19) 12.68 (3.38) 11.99 (3.85) 12.49 (4.70) 0.80
cIMT (mm) 0.83 (0.22) 0.80 (0.14) 0.79 (0.14) 0.83 (0.18) 0.43
Mean and standard deviation unless speciﬁed.
a Geometric mean (interquartile range).
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Fig. 2. Scatterplot and linear regression line of sRAGE and log NT-proBNP, log cTnT, AP and AIx in men without diabetes and with diabetes.
Men without diabetes: correlation coefﬁcient (r) between sRAGE and (i) NT-proBNP (r ¼ 0.15), (ii) AP (r ¼ 0.11), (iii) AIx (r ¼ 0.12) and (iv) cTnT (r ¼ 0.09). Men with diabetes:
correlation coefﬁcient (r) between sRAGE and (i) NT-proBNP (r ¼ 0.26), (ii) AP (r ¼ 0.18), (iii) AIx (r ¼ 0.16) and (iv) cTnT (r ¼ 0.29).
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Table 3
Multivariate linear regression models of the relations of SRAGE with cardiac markers and subclinical vascular measurements in men with and without diabetes.
Age-adjusted
b-coefﬁcient
(se)
p-value Model 1a
b-coefﬁcient
(se)
p-value Model 2b
b-coefﬁcient
(se)
p-value Model 3c
b-coefﬁcient
(se)
p-value
Men with no diabetes
Log NT-proBNP 0.32 (0.08) 0.0002 0.30 (0.09) 0.0007 0.29 (0.09) 0.001
Log cTnT 0.05 (0.04) 0.20 0.04 (0.04) 0.32 0.04 (0.04) 0.35
Augmentation pressure 0.99 (0.33) 0.003 1.08 (0.35) 0.002 0.75 (0.33) 0.02 0.70 (0.33) 0.04
Augmentation index 1.37 (0.41) 0.0008 1.52 (0.43) 0.0004 1.14 (0.40) 0.005 1.09 (0.40) 0.008
Men with diabetes
Log NT-proBNP 0.53 (0.18) 0.003 0.42 (0.20) 0.04 0.41 (0.20) 0.04
Log cTnT 0.31 (0.09) 0.0007 0.14 (0.09) 0.13 0.14 (0.09) 0.12
Augmentation pressure 1.61 (0.75) 0.03 1.42 (0.79) 0.07 1.59 (0.72) 0.03 1.43 (0.72) 0.05
Augmentation index 1.82 (0.92) 0.05 1.98 (0.99) 0.04 2.21 (0.89) 0.01 1.83 (0.89) 0.04
a Model 1:adjusted for age, BMI, eGFR, antihypertensive treatment, LDL-C, insulin and Il-6.
b Model 2:Model 1 þ heart rate.
c Model 3:Model 2þNT-proBNP.
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In this study of older men without prevalent CVD, sRAGE was
strongly and positively associated with renal dysfunction, as
observed in other studies [31], and related positively to NT-proBNP,
a marker of ventricular stress, as well as haemodynamic markers of
arterial wave reﬂection (AP and AIx), which are known to predict
CVD and HF [18e22,27]. Interestingly, levels of sRAGE were similar
in men with and without diabetes and these associations with NT-
proBNP, AP and AIx were seen in elderly men both with and
without diabetes. To our knowledge, this is the ﬁrst study to report
on the association between sRAGE and both cardiac and vascular
risk markers in those with and without diabetes from within the
same population. Our ﬁndings of a positive association between
sRAGE and both NT-proBNP and haemodynamic parameters known
to be associated with CVD risk supports prospective studies that
have shown sRAGE to be positively associatedwith increased risk of
incident CVD in diabetes and in older adults and provides further
insight into upstream pathways by which sRAGE may inﬂuence
clinical development of CVD.
4.1. sRAGE and CVD
Although a number of cross sectional and prospective studies
have shown inverse associations between sRAGE and risk of CVD,
several other prospective studies, particularly in diabetes and the
elderly, have shown sRAGE to be positively associated with
increased risk of CVD [8e12]. We have also shown sRAGE to be
signiﬁcantly elevated in those with prevalent CVD, which is
consistent with other reports of positive associations between
sRAGE and CVD in diabetes and in older adults [8e12]. It is sug-
gested that in states of increased AGEs, such as in people with
diabetes and in older populations, RAGE expression is increased [8].
Thus, sRAGE in diabetes or in older adults may reﬂect the activity of
the AGE-RAGE axis [10].
4.2. sRAGE, subclinical arterial disease and central haemodynamics
No association was seen between sRAGE and carotid athero-
sclerosis, which is consistent with ﬁndings from the NOMAS study
of older adults [32]. We also found no association between sRAGE
and arterial stiffness, as measured by carotid to femoral PWV and
carotid distensibility, and only a weak positive association with
central aortic pulse pressure. Previous work examining the rela-
tionship between sRAGE and arterial stiffness has been inconsis-
tent, with some studies showing positive associations [33] andothers ﬁnding inverse associations [34]. By contrast, a signiﬁcant
association was seen between sRAGE and AP and AIx, even after
adjustment for CVD risk factors including BMI, renal function,
metabolic risk markers, inﬂammation and heart rate. The associa-
tion between sRAGE and both AP and AIx was partially accounted
for by its relationship with NT-proBNP. Although AP and AIx have
been used as indirect clinical indices of arterial stiffness, they are
also importantly inﬂuenced by the timing and magnitude of wave
reﬂections and are considered important measures of wave re-
ﬂections [35]. Central AIx has also been shown to be affected by
changes in LV ejection time and systolic loading [36]. The AIx,
which may represent an increase in wave reﬂections and also serve
as a marker of LV afterload, has been associated with impaired left
ventricular systolic and diastolic function [37,38], which may her-
ald the development of clinically overt heart failure. Data on the
relationship between sRAGE and AP and AIx are limited and further
studies are needed to conﬁrm these ﬁndings and their clinical
signiﬁcance.4.3. sRAGE and cardiac function
We have observed a positive association between sRAGE and
NT-proBNP, a marker of left ventricular stress, but not with cTnT, a
marker of myocardial damage. NT-proBNP is a cardiac hormone
secreted frommyocytes in response to ventricular and arterial wall
stress and is predictive of CVD and HF [27]; circulating levels of NT-
proBNP are increased in both LV systolic and diastolic dysfunction.
Mechanical stress on cardiac myocytes stimulates secretion of NT-
proBNP, and central haemodynamic indices may, at least in part,
indicate left ventricular loading conditions. Several lines of evi-
dence suggest that AGEs are related to the development and pro-
gression of HF in both diabetic and non-diabetics patients [2].
Clinical studies in animals have also found that compliance of the
left ventricle decreases with accumulation of AGEs in the myocar-
dium and implicated AGEs in the development of both diastolic and
systolic heart failure. The positive association we found between
sRAGE and AP, AIx and NT-proBNP in men both with and without
diabetes is consistent with these assertions and may reﬂect a direct
effect of the AGE-RAGE system on left ventricular loading and
function. This may explainwhy sRAGE is associated with the AP/AIx
and NT-proBNP, but not large artery stiffness as characterised by
aortic PWV, distensibility or cIMT in both men with and without
diabetes in our study. Individuals with diabetes are at particularly
high risk of CVD and HF [39] and RAGE may be a mechanism by
which diabetes may lead to left ventricular dysfunction and even-
tually HF. Although sRAGE has been shown to be elevated in
S.G. Wannamethee et al. / Atherosclerosis 264 (2017) 36e4342patients with HF [40], studies on sRAGE and incident HF risk are
sparse, with only one prospective study conducted in middle-aged
adults showing an inverse association between sRAGE and incident
HF [41]. It is possible that sRAGE has differing relationships in
differing states of increased AGEs; for example sRAGE in older
adults and people with diabetes may reﬂect the level of RAGE
expression.
4.4. Strengths and limitations
The study is a geographically representative sample of older
British men and we are not aware of previous studies describing
associations between sRAGE and awide range of cardiovascular risk
factors and vascular measurements in a large population-based
sample of older people both with and without diabetes in whom
AGEs are increased. The issue of survivor bias is inevitable in co-
horts of ageing populations, with subjects with diabetes and CVD
likely to have died at a higher rate. The results presented in this
study are also subject to the sampling bias by the moderate
response rate for the clinical examination (55%), which is also likely
to have excluded participants in worse health; men who partici-
pated in our study were healthier than those who did not. These
factors may have resulted in some of the null ﬁndings seen between
sRAGE and vascular measurements such as cIMT and arterial stiff-
ness. Nevertheless, we have observed signiﬁcant associations be-
tween sRAGE and central haemodynamics (arterial wave
reﬂections) and NT-proBNP in men with no prior clinical diagnosis
of CVD. sRAGE was based on one measurement, however, concen-
trations of sRAGE within individuals have shown to be relatively
stable over three years [42]. Another limitation of our study is that
it comprises only white European men, and the generalizability of
the study towomen and other ethnic groups is limited. Our ﬁndings
are based on associations with biological markers associated with
cardiac dysfunction. Cardiac imaging measurements were not
available and we do not have any direct data on LV systolic/diastolic
function or ventricular-arterial interaction. We also acknowledge
that our results are based on cross-sectional analyses, therefore, we
cannot infer the direction of causation in the associations observed.
Our study cannot address the question of whether sRAGE would be
a useful clinical tool to assess CVD or HF risk based on cross
sectional ﬁndings. Nevertheless, the association with wave reﬂec-
tion and cardiac dysfunction (NT-proBNP) may help towards un-
derstandingmechanisms and pathways bywhich elevated sRAGE is
associated with increased risk of CVD/HF in diabetic patients.
Further prospective studies and clinical studies are warranted to
investigate the potential clinical usefulness of measuring sRAGE in
clinical practice.
4.5. Conclusion
Higher plasma sRAGE is associated with increased NT-proBNP
and arterial wave reﬂections (AP and AIx) in both older men with
and without diabetes, but not with cIMT or arterial stiffness. These
ﬁndings suggest that sRAGE as a marker of augmented AGE-RAGE
signalling activity may contribute to or be a marker of worsening
cardiac dysfunction and HF and thusmay be a potential mechanism
by which dysglycemia and diabetes lead to increased risk of HF.
Cardiac imaging data are required to conﬁrm these ﬁndings. Future
prospective studies are warranted to investigate the association
between sRAGE and development of HF in older adults with and
without diabetes.
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